• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of sexual medicine >Sildenafil 25 mg ODT?+ Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison Analysis
【24h】

Sildenafil 25 mg ODT?+ Collagenase Clostridium hystoliticum vs Collagenase Clostridium hystoliticum Alone for the Management of Peyronie’s Disease: A Matched-Pair Comparison Analysis

机译：Sildenafil 25 mg Odt？+胶原酶蛋白酶酸纤维素酸杂交菌与胶原酶蛋白酸血糖菌株单独用于治疗PEYRONIE疾病的管理：匹配对比较分析

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

IntroductionThe effectiveness of phosphodiesterase type 5 (PDE5) inhibitors over the conservative management of Peyronie’s disease (PD) has been widely questioned. AimTo determine the role of sildenafil 25 mg film formulation twice a day (S25 b.i.d.) in the improvement of curvature after treatment of collagenase ofClostridium hystoliticum(CCH) in penile curvature owing to PD. MethodsFrom April 2017 to April 2018, 161 consecutive patients were treated with S25 b.i.d.?+ CCH or CCH alone. Adjustment variables consisted of age, penile curvature, and the 15-question International Index of Erectile Function (IIEF-15) questionnaire at baseline using 1:1 propensity-score matching. Overall, 50 patients were considered subdivided into the following: 25 patients who received S25 b.i.d.?+ CCH (group A) and 25 who received CCH alone (group B). Patients received CCH injection using a shortened protocol and vacuum device in both groups. Main Outcome MeasureThe primary outcome of the study was the change in penile curvature after treatment, and secondary outcomes were the change in sexual function (IIEF-15) and in the Peyronie’s Disease Questionnaire (PDQ) and its subscores, PDQ-PS (psychosexual symptoms), PDQ-PP (penile pain), and PDQ-SB (symptom bother). ResultsOverall, mean penile curvature was 47.0° (SD 21.88), the mean IIEF-EF (erectile function) was 23.56 (SD 4.10), and the mean PDQ was 27.06 (SD 13.55). After the treatment, we observed a mean change for penile curvature of 25.6 (SD 9.05) in group A and –25.6 (SD 9.7) in group B (P< .01), for IIEF-EF of 2.28 (SD 2.33) in group A and 1.36 (SD 1.77) in group B (P?= .03), for PDQ-PS of –3.04 (SD 2.95) in group A and of –2.12 (SD 2.06) in group B (P?= .11), for PDQ-PP of –1.0 (SD 4.48) in group A and of –0.88 (SD 2.04) in group B (P?= .60), for PDQ-SB of –5.84 (SD 4.58) in group A and of –4.16 (SD 4.45) in group B (P?= .60), and for Female Sexual Function Index of 3.8 (SD 2.45) in group A and of 2.72 (SD 2.28) in group B (P?= .14). We found a rate of global satisfaction of 70.83% in group A and of 84.0% in group B (P?= .27). Clinical ImplicationsAddition of S25 b.i.d. to CCH is superior to CCH alone for improving penile curvature and erectile function. Strength & LimitationsThis is the first study comparing sildenafil?+ CCH vs CCH alone for the treatment of PD. Lack of randomization and direct verification of appropriate use of penile modeling could be considered limitations. ConclusionIn this study, combination therapy was superior in terms of penile curvature and erectile dysfunction improvement.Cocci A, Cito G, Urzì D, et?al. Sildenafil 25 mg ODT?+ collagenaseClostridium hystoliticumvs collagenaseClostridium hystoliticumalone for the management of Peyronie’s disease: A matched-pair comparison analysis. J Sex Med 2018;15:1472–1477.
机译：引言磷酸二酯酶类型5（PDE5）抑制剂在PEYRONIE疾病（PD）保守管理中的有效性得到了广泛质疑。目的在通过Pd治疗阴茎曲率下治疗Clostridum（CCH）后曲脂酶后的曲率改善，确定西地那非25mg薄膜制剂的作用（S25 B.I.D.）。方法从2017年4月到2018年4月，连续161名患者单独使用S25 B.I.D.? + CCH或CCH治疗。调整变量由年龄，阴茎曲率和勃起函数（IIEIE-15）问卷的15个问题使用1：1倾向分数匹配组成。总体而言，50名患者被认为细分为以下内容：25名接受S25 B.I.D.DCCH（A组）和25名接受CCH的患者（B组）。患者通过两组中使用缩短的方案和真空装置接受CCH注射。主要结果测量研究的主要结果是治疗后阴茎曲率的变化，二次结果是性功能（IIEIIE-15）和PEYRONIE疾病调查问卷（PDQ）及其子科（精神症状） ），PDQ-PP（阴茎疼痛）和PDQ-SB（症状麻烦）。结果转移，平均阴茎曲率为47.0°（SD 21.88），平均IIEIE-EF（勃起函数）为23.56（SD 4.10），平均PDQ为27.06（SD 13.55）。治疗后，在B组（P <0.01）中，在B组（P <.01）中，观察到25.6（SD 9.05）的阴茎曲率的平均变化为2.28（SD 2.33）的IIEIE-EIEIAI-EIEAI-EIEIAI B组（p？= .03）中的A和1.36（SD 1.77），在B组A和-2.12（SD 2.06）中的-3.04（SD 2.95）的PDQ-PS（P？= .11） ，对于A组A和-0.88（SD 2.04）的-1.0（SD 4.48）的PDQ-PP（P？= .60），用于组A和A的PDQ-SB（SD 4.58） -4.16（SD 4.45）在B组（p？= .60）中，在B组A和2.72（SD 2.28）中的3.8（SD 2.45）的女性性功能指数（P？= .14）。我们发现A组和B组的全球满意度为70.83％（B组（P？= .27）。 S25 B.I.D的临床意义加入。 CCH优于CCH，仅用于改善阴茎曲率和勃起功能。强度和限制是第一次对比较西地那非的研究单独用于治疗PD的研究。缺乏随机化和直接验证适当使用阴茎建模可能被视为局限性。结论本研究，联合治疗在阴茎曲率和勃起功能障碍改善方面优越.CC1，Cito G，Urzìd，等。 Sildenafil 25 mg Odt？+ CollagenaseClostridium hystoliticumvs Collagenaseclostridium hystoliticumalone用于Peyronie疾病的管理：匹配对比较分析。 J SEX MED 2018; 15：1472-1477。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号